Aclaris Therapeutics, Inc. (0H8T.L)
USD 1.38
(3.29%)
USD 1.38
(3.29%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -85.21 Million USD | -578.96% |
| 2022 | 17.79 Million USD | 768.75% |
| 2021 | 2.04 Million USD | 51.82% |
| 2020 | 1.34 Million USD | 684.3% |
| 2019 | 172 Thousand USD | -90.56% |
| 2018 | 1.82 Million USD | 282.77% |
| 2017 | 476 Thousand USD | 496.67% |
| 2016 | -120 Thousand USD | -33.33% |
| 2015 | -90 Thousand USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 558 Thousand USD | -94.99% |
| 2024 Q2 | -7.9 Million USD | -1516.13% |
| 2023 Q3 | 8.43 Million USD | 919.83% |
| 2023 Q1 | 1.72 Million USD | -72.43% |
| 2023 FY | 13.16 Million USD | -25.99% |
| 2023 Q2 | 827 Thousand USD | -51.92% |
| 2023 Q4 | 11.14 Million USD | 32.11% |
| 2022 Q2 | 460 Thousand USD | 54.36% |
| 2022 FY | 17.79 Million USD | 768.75% |
| 2022 Q4 | 6.23 Million USD | -65.52% |
| 2022 Q3 | 18.09 Million USD | 3833.7% |
| 2022 Q1 | 298 Thousand USD | -15.34% |
| 2021 Q2 | 561 Thousand USD | -2.43% |
| 2021 Q1 | 575 Thousand USD | 106.64% |
| 2021 Q3 | 560 Thousand USD | -0.18% |
| 2021 Q4 | 352 Thousand USD | -37.14% |
| 2021 FY | 2.04 Million USD | 51.82% |
| 2020 Q1 | -7.53 Million USD | 34.43% |
| 2020 FY | 1.34 Million USD | 684.3% |
| 2020 Q2 | -5.8 Million USD | 22.95% |
| 2020 Q3 | -5.98 Million USD | -2.94% |
| 2020 Q4 | -8.66 Million USD | -44.85% |
| 2019 Q3 | -16.02 Million USD | 5.13% |
| 2019 Q1 | -19.58 Million USD | -6.18% |
| 2019 FY | 172 Thousand USD | -90.56% |
| 2019 Q4 | -11.49 Million USD | 28.26% |
| 2019 Q2 | -16.89 Million USD | 13.75% |
| 2018 Q4 | -18.44 Million USD | -21.86% |
| 2018 FY | 1.82 Million USD | 282.77% |
| 2018 Q3 | -15.13 Million USD | -30.8% |
| 2018 Q1 | -12.58 Million USD | -5238.37% |
| 2018 Q2 | -11.57 Million USD | 8.07% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q3 | 231 Thousand USD | 0.0% |
| 2017 Q4 | 245 Thousand USD | 6.06% |
| 2017 FY | 476 Thousand USD | 496.67% |
| 2016 FY | -120 Thousand USD | -33.33% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | -90 Thousand USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| uniQure N.V. | 2.21 Million USD | 3947.223% |
| Abeona Therapeutics Inc. | 302 Thousand USD | 28317.219% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 592.038% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | -27125.559% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 676.017% |
| Imunon, Inc. | -720 Thousand USD | -11735.473% |
| Dynavax Technologies Corporation | 182.11 Million USD | 146.792% |
| Editas Medicine, Inc. | -99.52 Million USD | 14.38% |
| FibroGen, Inc. | 128.9 Million USD | 166.108% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | -790.822% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | -28024.092% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 104.613% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 107.797% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 116.271% |
| Verastem, Inc. | -62 Thousand USD | -137345.161% |
| Zoetis Inc. | 5.83 Billion USD | 101.461% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 100.99% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | -88.011% |
| Homology Medicines, Inc. | -7.22 Million USD | -1078.808% |
| Nektar Therapeutics | 53.47 Million USD | 259.348% |
| Viking Therapeutics, Inc. | -292 Thousand USD | -29083.562% |
| Unity Biotechnology, Inc. | -19.69 Million USD | -332.59% |
| Perrigo Company plc | 1.68 Billion USD | 105.071% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 216.627% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 100.321% |
| Illumina, Inc. | 2.74 Billion USD | 103.106% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 100.56% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 101.627% |
| Heron Therapeutics, Inc. | 10.04 Million USD | 948.596% |
| Waters Corporation | 1.76 Billion USD | 104.839% |
| Biogen Inc. | 7.3 Billion USD | 101.167% |
| Evolus, Inc. | 140.52 Million USD | 160.641% |
| Adicet Bio, Inc. | -6.09 Million USD | -1297.442% |
| bluebird bio, Inc. | -4.03 Million USD | -2014.541% |
| Geron Corporation | -123.5 Million USD | 31.001% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 105.614% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 123.538% |
| Myriad Genetics, Inc. | 476.4 Million USD | 117.887% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 78.632% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 103.929% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | -173.412% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 104.475% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 100.754% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 102.459% |
| OPKO Health, Inc. | 318.12 Million USD | 126.787% |
| Exelixis, Inc. | 1.75 Billion USD | 104.848% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 117.907% |
| Anavex Life Sciences Corp. | - USD | Infinity% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 134.848% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 110.946% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 113.38% |
| Blueprint Medicines Corporation | 236.58 Million USD | 136.019% |
| Insmed Incorporated | 239.63 Million USD | 135.561% |
| TG Therapeutics, Inc. | 219.1 Million USD | 138.892% |
| Incyte Corporation | 3.44 Billion USD | 102.477% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 124.779% |